Since high expression of B-Myb is oncogenic and serves as clinical marker of poor prognosis in breast and other cancers (Iness and Litovchick, 2018), further mechanistic studies of its effect on the DYRK1A substrate LIN52 are justified. This evidence concerns the gene DYRK1A and cancer.